VICP
Vicapsys Life Sciences, Inc.1.5000
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
48.56MP/E (TTM)
-Basic EPS (TTM)
-0.03Dividend Yield
0%Recent Filings
10-Q
Q3 FY2024 results
Vicapsys Life Sciences posted a $235,507 net loss for Q3 2024 ended September 30, up 2% y/y from $240,340, while nine-month losses widened to $752,670 from $587,309 amid higher professional fees for consulting. Operating expenses climbed 13% y/y to $198,862 in the quarter, driven by personnel costs and related-party R&D under the MGH license, yet cash burn eased to $43,687 for nine months versus $335,470 last year. Cash rose to $89,569 from $9,422 at year-end, fueled by $123,834 in financing including $95,000 convertible notes and $55,000 promissory note, though total liabilities ballooned to $2.7M with $511,403 in convertibles at 10% rates maturing soon. No revenues yet, but the team persists. Defaults loom on notes and MGH milestones.
10-Q
Q2 FY2024 results
Vicapsys Life Sciences posted no revenue for Q2 FY2024 ended June 30, 2024, with operating expenses climbing 34% y/y to $181,841, driven by higher professional fees for consulting, while personnel costs held steady at $62,500. This yielded an operating loss of $181,841, up from $135,693 last year, and a net loss of $190,091 after $8,250 in interest—net loss widened 40% y/y for the quarter but trailed the $327,072 Q1 loss. For the half-year, net loss reached $517,164, or $(0.02) per diluted share on 34.2M shares, consistent with YTD figures and no anti-dilution effects. Cash dwindled to zero from $9,422 at year-end, with net operating cash use at just $3,256 amid $2.4M current liabilities including a $449K convertible note due October 2024 (now waived to year-end). Subsequent $95K and $55K notes bolster liquidity, yet funding shortfalls persist. Regulatory hurdles loom large in advancing CXCL12 tech toward FDA trials.
10-Q
Q1 FY2024 results
Vicapsys Life Sciences posted no revenue for Q1 2024 ended March 31, while operating expenses dipped 3.3% y/y to $204,255, yielding an operating loss of $204,255—better than the prior year's $211,277. Yet net loss widened 55% y/y to $327,072, or $(0.01) per diluted share on 32,071,299 weighted shares, driven by $36,517 in interest and $86,300 loss on debt extinguishment from convertible note amendments. Cash drained to zero from $9,422 at year-end, with net operating cash use steady at $9,422; free cash flow not disclosed in the 10-Q. Total current liabilities climbed to $2.26M, including a $449,300 convertible note (now extended to October 2024 but in default) and related-party payables, against no assets. The company lags MGH license milestones, negotiating extensions amid funding hunts. Cash is gone.
10-K
FY2023 results
Vicapsys Life Sciences posted a net loss of $1.18 million for FY2023 ended December 31, 2023, up 20% from $0.98 million in FY2022, driven by higher professional fees for a NASDAQ uplisting push and elevated director compensation, while R&D ticked up modestly to $15,267 from $13,097. No revenues emerged in either year, underscoring the pre-revenue biotech grind, with Q4 mirroring annual trends amid stalled milestones like unmet $2 million financing targets under the MGH license. Cash dwindled to $9,422 by year-end, fueling a $1.93 million working capital deficit and going-concern warnings; a $100,000 private placement and $290,350 net from a $330,000 convertible note offered scant relief. No dividends or buybacks surfaced, but integration of the impaired MGH intangible lingers as a drag. Regulatory delays in clinical trials could further stall quarterly momentum.
8-K
Vicapsys extends debt maturity
Vicapsys Life Sciences amended its June 2023 securities purchase agreement and promissory note with AJB Capital Investments on December 26, 2023, extending the note's maturity to January 27, 2024, and boosting principal from $330,000 to $363,000. This one-time tweak also pushes the SEC registration deadline for resale shares to the same date, buying the biotech extra runway amid funding pressures. Accrued interest falls due then. Deadlines loom tight.
CLCS
Cell Source, Inc.
0.45+0.08
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
FBRX
Forte Biosciences, Inc.
23.27+1.31
PMCB
PharmaCyte Biotech, Inc.
0.95+0.01
SEPSF
ASEP Medical Holdings Inc.
0.01+0.00
TLSA
Tiziana Life Sciences Ltd
1.55-0.04
VCEL
Vericel Corporation
35.50-0.99
VINC
Vincerx Pharma, Inc.
0.01+0.00
VIVS
VivoSim Labs, Inc.
1.99+0.01
ZIVO
Zivo Bioscience, Inc.
9.00+0.00